Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended ...

Novavax (NVAX) stock in focus as the company boosts 2025 revenue outlook after better than expected Q3 revenue driven by ...

Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the U.S. marketing authorization for its COVID-19 vaccine, ...

Fintel reports that on November 10, 2025, B. Riley Securities reiterated coverage of Novavax (NasdaqGS:NVAX) with a Buy ...

Shah Capital increased its stake to about 8.3% and said the gap between Novavax’s scientific potential and its commercial ...

Discover Novavax's Q3 2025 earnings: partnership-driven strategy, cost savings, increased revenue outlook, and pipeline progress.

Novavax on Thursday provided preliminary adjusted revenue for 2026 and pushed back its profitability target by a year to 2028 as the biotech awaits key product launches from its partnership with ...

GAITHERSBURG, Md. (AP) — GAITHERSBURG, Md. (AP) — Novavax Inc. (NVAX) on Thursday reported a loss of $202.4 million in its third quarter. On a per-share basis, the Gaithersburg, Maryland-based company ...

Analysts expect Novavax to report an earnings per share (EPS) of $-0.96. Anticipation surrounds Novavax's announcement, with investors hoping to hear about both surpassing estimates and receiving ...

Wondering if Novavax is a hidden bargain or just another biotech roller coaster? You are not alone, and getting to the bottom of its real value is more important than ever. Despite plenty of buzz, ...

Novavax raised its annual revenue forecast for the third time this year on Thursday, banking on milestone payments from ...